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ABSTRACT There exists a paucity of data for socially disadvantaged populations describing patterns and
predictors of asthma control status and exacerbations during pregnancy, and their relationship to adverse
perinatal outcomes.
Asthmatic women (n=189) were followed prospectively during pregnancy, with visits at 12, 20, 28 and
36 weeks gestation. Data on loss of control, recurrent uncontrolled asthma and moderate/severe
exacerbations were collected at each visit and their relationship to perinatal outcomes examined following
stratification for fetal sex.
50% of asthmatic women experienced a loss of control or moderate/severe exacerbation during
pregnancy, with 22% of women experiencing a moderate/severe exacerbation. Factors associated with an
increased risk of women experiencing recurrent uncontrolled asthma during pregnancy included smoking
(relative risk 2.92, 95% CI 1.53–5.58), inhaled corticosteroid use at the beginning of pregnancy (relative
risk 2.40, 95% CI 1.25–4.60) and increasing maternal age (relative risk 1.06, 95% CI 1.01–1.11). No factors
were associated with moderate/severe exacerbations. Asthma control rather than exacerbations during
pregnancy appeared to be most strongly correlated with perinatal outcomes. Following stratification by
fetal sex, the presence of recurrent uncontrolled asthma was associated with an increased risk of being
small for gestational age in women pregnant with females (33.3% versus 9.5%; p=0.018). In contrast, there
was a nonsignificant increased risk of preterm birth in women with recurrent uncontrolled asthma that
were pregnant with males (25.0% versus 11.8%; p=0.201)
These results suggest that the key to improving perinatal outcomes lies in improving asthma control as
early as possible in pregnancy and monitoring throughout pregnancy, rather than focusing on preventing
exacerbations alone.
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The adverse effects of asthma in pregnancy are related to asthma severity and the intensity of treatment
[1–3]. Acute asthma exacerbations have been identified as the most significant event to affect fetal
morbidity and mortality in pregnancies complicated by asthma [4, 5]. A number of studies have examined
the effects of maternal asthma during pregnancy, in the presence and absence of inhaled corticosteroid
(ICS) treatment, on placental function and fetal development [6]. These studies have demonstrated that
use of ICS for the treatment of asthma did not affect fetal growth, and that maternal asthma without
treatment had a greater impact on the fetus and placenta [7]. Overall, the evidence clearly demonstrates no
increased risk of adverse maternal or fetal complications in situations where asthma is well controlled
throughout pregnancy [8, 9]. In contrast, poor asthma control, as indicated by the need for more intensive
treatment, is a greater risk factor for an adverse outcome during pregnancy than ICS use [5]. Further,
regular use of oral corticosteroids (OCS), used in the management of acute asthma exacerbations and
poorly controlled asthma during pregnancy, has been associated with an increased incidence of low birth
weight babies and preterm birth [10]. These findings highlight the importance of optimising asthma
control and reducing asthma exacerbations.
Previous studies have defined asthma exacerbations as any asthma-related event that involved one or more
of the following: a hospital admission, an unscheduled visit to a doctor, a course of oral steroids, an
increase in medication use or decreased peak expiratory flow rate. Among those with mild, moderate and
severe asthma the exacerbation rates have been reported as 13%, 26% and 52%, respectively [11]. The
corresponding rates of exacerbations leading to hospitalisation were 2%, 7% and 27% [11]. Relying solely
on asthma severity, however, can be misleading as asthma can worsen during pregnancy regardless of
maternal pre-pregnancy severity [4, 5]. Exacerbations can occur at any time during gestation, but are most
likely in the second and third trimesters between weeks 17 and 34, with peak incidence at around
25 weeks gestation. Many interventions for pregnant asthmatic women are focused on reducing asthma
exacerbations as it is likely to have the greatest impact on improving perinatal outcomes [12].
A major comorbidity of pregnant women with asthma is cigarette use [13, 14]. We previously found that
25% of asthmatic women smoked during pregnancy relative to 17% of non-asthmatic women [14].
Asthmatic women who were current smokers during pregnancy had more severe asthma exacerbations
during pregnancy relative to women who were nonsmokers [15]. The combination of asthma and cigarette
use also significantly increased the incidence of low birth weight neonates and preterm deliveries [14].
It is recognised that social disadvantage encompasses a range of contributing factors including health
literacy, income, occupation, housing, health behaviours (i.e. smoking and poor diet) and comorbidities
(i.e. mental health) as well as race and/or ethnicity. The prevalence of asthma is greatest among those
living in lower socioeconomic status areas, with low socioeconomic status also associated with almost
double the rate of smoking, increased rates of hospitalisations for asthma and an increased risk of
asthma-related mortality [16]. Children from low socioeconomic status communities are more likely to
have poorly controlled asthma relative to children of high socioeconomic status [17] and it has been
proposed that socioeconomic status index is a strong predictor of poor asthma outcomes. The BIOAIR
study demonstrated that low socioeconomic status is a risk factor for exacerbations [18]. However, poor
asthma control and exacerbations in low socioeconomic status populations may be due to inadequacies in
health literacy [19]. APTER et al. [20] reported that reduced literacy and numeracy skills in association with
ethnicity, age, income and educational attainment were all associated with level of asthma control, with
those individuals with reduced literacy being more likely to have uncontrolled asthma.
In the current study, we have examined asthma control and exacerbations in a group of pregnant women
who live in a socially disadvantaged community in South Australia. The level of social deprivation in this
pregnant population is significant. For example, 36% of pregnant women from this population have
reported they were abused as children, 35% have suffered major life stressors and 30% of these pregnant
women were diagnosed with depression during antenatal care [21]. Population-based data report that 40%
of the inhabitants in this community do not finish year 10 of high school, >22% of the population are
unemployed, 27% are housed by the government and 22% of families have a sole female parent [22]. Our
objective was to examine patterns and predictors of asthma control and exacerbations during pregnancy in
a population of women from a socially disadvantaged community, and to determine the association of this
data with perinatal outcomes.
Methods
Approval for the study was provided by The Queen Elizabeth Hospital, Lyell McEwin Hospital and
Modbury Hospital Human Research Ethics Committee and The University of Adelaide Human Research
Ethics Committee. All women gave written informed consent.
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Prospective asthma study
Pregnant women with a doctor diagnosis of asthma (n=189) were recruited through the Lyell McEwin
Hospital antenatal clinics (South Australia, Australia) between May 2009 and May 2012 to take part in a
non-interventional prospective cohort study evaluating the impact of maternal asthma on perinatal
outcomes. Women were assessed by a midwife, with additional respiratory training, at 12, 20, 28, and
36 weeks gestation. The midwife utilised a standardised data collection tool to collect demographic data
including maternal weight, height, previous obstetric history and medical history. Maternal smoking was
assessed by maternal self-report, with women classified according to smoking status during the first
antenatal visit. Socioeconomic status for each woman was determined using her residential postcode at the
time of delivery. Women were then ranked according to their level of advantage, or relative disadvantage,
based on data from the Socio-Economic Indexes for Areas, calculated from the Australian Bureau of
Statistics’ 5-yearly Census of Population and Housing. These indexes are widely used measures of relative
socioeconomic status [2]. In addition to demographic variables, data were collected to determine current
asthma therapy and control, current asthma triggers, comorbidities and past history including frequency of
OCS use and hospital admissions for asthma. Asthma control was assessed using the Asthma Control
Questionnaire (ACQ). The ACQ is a seven-item validated questionnaire which covers asthma symptoms
and lung function, with scores >1.5 indicative of uncontrolled asthma [23]. Forced expiratory volume in
1 s (FEV1) and forced vital capacity (FVC) were measured using an Easy One spirometer (ndd Medical
Technologies, Inc., Andover, MA, USA) before and after administration of salbutamol. FEV1 % predicted
was calculated based on the patient’s age, ethnicity and height using the equations of GORE et al. [24]. Data
were prospectively collected on asthma medications (dose, frequency and duration across trimesters). The
same midwife saw women for each of their respective visits. Patients assessed as unstable and requiring
medical review were referred to their primary care physician or to a respiratory physician.
Maternal asthma and perinatal outcomes
Details of the exacerbations were obtained from the study visit notes and confirmed by consulting the
medical record if necessary. An exacerbation event was defined as moderate/severe if it required a hospital
admission, emergency department presentation, an unscheduled visit to a doctor or a course of oral
steroids due to asthma. A loss of control was defined as an increase in asthma symptoms or an increase in
medication use, which was managed by the subject and did not require medical intervention, or an ACQ
score of >1.5 during an asthma study visit. Most women were identified as having a loss of control using
the ACQ score at a study visit. An additional asthma outcome included recurrent uncontrolled asthma,
defined as an ACQ score of >1.5 during two or more study visits. Data were prospectively collected at each
study visit. Data on perinatal outcomes were collected at delivery from the medical records, including
infant sex, gestational age, birthweight, birth length, head circumference, method of delivery and Apgar
scores. Gestational age was determined by the date of the last menstrual period and confirmed by
ultrasound at 18 weeks. Preterm birth was defined as <37 completed weeks gestation, while small for
gestational age (SGA) was defined according to birthweight (<10th percentile for gestational age).
Statistical analysis
The impact of various maternal characteristics on asthma exacerbations and recurrent uncontrolled asthma
during pregnancy were examined using a generalised linear model, generating relative risks and 95%
confidence intervals. The impact of asthma exacerbations and recurrent uncontrolled asthma on perinatal
outcomes were examined using unpaired t-tests for parametric continuous variables, and Fisher’s exact test
for categorical variables, following stratification for infant sex. All reported p-values were two-tailed, and a
p-value of <0.05 was considered to be statistically significant. All statistical procedures were carried out
using SPSS version 19 (SPSS Inc., Chicago, IL, USA).
Results
Pregnant women with asthma (n=189) were more likely to be overweight (24%) or obese (35%) than of
normal weight (40%). They were predominantly Caucasian and in the lowest two quintiles for
socioeconomic status (85%). One third of women were treated with an ICS during pregnancy and 78% of
those women were using a combination drug of an ICS with a long-acting β2-agonist. 54% of asthmatic
women did not use an ICS during pregnancy and 13.8% of women were prescribed an ICS during
pregnancy. 20% of asthmatics were current smokers. Overall, 22% of women experienced a moderate/severe
exacerbation during pregnancy, 50% of women had a loss of control during gestation and 16% had recurrent
uncontrolled asthma as indicated by more than two episodes where the ACQ score was >1.5 (table 1).
The percentage of women who experienced an exacerbation or loss of control (figure 1a) increased linearly
as gestation progressed. Similarly, the percentage of exacerbations and loss of control also increased as
gestation progressed (figure 1b), which was comparable to the number of exacerbations or loss of control
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throughout gestation for the entire population (figure 1c). Overall there were more asthmatic women
identified with a loss of asthma control (50%) as gestation progressed than with an exacerbation (22%).
When examining the relative risk of a severe exacerbation there were no significant maternal characteristics
that contributed to an exacerbation during pregnancy (table 2). However, maternal age, normal body mass
index (BMI) and quitting smoking appeared protective against an exacerbation during pregnancy. Baseline
ICS was a nonsignificant predictor of exacerbation risk. The presence of an asthma exacerbation during
pregnancy was not associated with any statistically significant increase in adverse perinatal outcomes (table 3).
Interestingly, there were significant associations between maternal characteristics and the presence of
recurrent uncontrolled asthma in this cohort (table 4). Women with uncontrolled asthma were older (relative
risk 1.06, 95% CI 1.01–1.11), overweight (relative risk 1.89, 95% CI 0.89–4.04), current smokers (relative risk
2.92, 95% CI 1.53–5.58) and prescribed an ICS (possibly a reflection of asthma severity) (relative risk 2.40,
95% CI 1.25–4.60) (table 4). Following stratification by fetal sex, the presence of recurrent uncontrolled
TABLE 1 Maternal characteristics for the entire cohort
Subjects n 189
Maternal age years 26.1±5.5
BMI kg·m−2 28.4±7.2
BMI category
Normal weight 76 (40.2)
Overweight 46 (24.3)
Obese 67 (35.4)
Weight gain during pregnancy kg 10.7±6.5
Socioeconomic status











Never/former smoker 128 (67.7)
Quit smoking during pregnancy 23 (12.2)






ICS + LABA 48 (78.7)
Spirometry
FEV1 L 3.02±0.43
FEV1 % pred 92±11
FVC L 3.70±0.56
FEV1/FVC 0.82±0.06
New ICS in pregnancy
No 102 (54)
Yes 26 (13.8)
Using ICS pre-pregnancy 61 (32.3)
Any severe exacerbation 41 (21.7)
OCS use 14 (7.4)
General practitioner visit 31 (16.4)
Emergency department visit 10 (5.3)
Admitted to hospital 2 (1.1)
Persistent uncontrolled asthma 30 (15.9)
Data are presented as mean±SD or n (%), unless otherwise stated. BMI: body mass index; ICS: inhaled
corticosteroid; LABA: long-acting β2-agonist; FEV1: forced expiratory volume in 1 s; FVC: forced vital
capacity; OCS: oral corticosteroid.
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asthma at two or more study visits was associated with an increased risk of SGA (33.3% versus 9.5%;
p=0.018), but not preterm birth (11.1% versus 9.5%; p=1.000) among women pregnant with females
(table 5). By contrast, a nonstatistically significant increased risk of preterm birth was observed for males
(25.0% versus 11.8%; p=0.201), but not SGA (8.3 versus 11.8%; p=1.000) (table 5).
Discussion
This research identified that asthma worsened as gestation progressed in a linear fashion with the greater
proportion of women experiencing a loss of control rather than an exacerbation. The women who had
recurrent losses of control during pregnancy were significantly more likely to have a poor perinatal
outcome than the women who exacerbated during pregnancy, suggesting long periods of uncontrolled
asthma may be more harmful than acute exacerbations for the fetus specifically in relation to fetal growth.
Interestingly, half of all exacerbations and recurrent losses of control occurred before 20 weeks of gestation,
indicating that peri-conceptional interventions and early diagnosis of pregnancy followed by the
immediate introduction of asthma education and self-management skills may be essential for preventing
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FIGURE 1 Examination of the prevalence of asthma exacerbations and loss of asthma control throughout pregnancy in women with asthma. A loss
of control was defined as an increase in asthma symptoms or an increase in medication use, which was managed by the subject and did not require
medical intervention, or an Asthma Control Questionnaire score of >1.5 during an asthma study visit. An exacerbation event was defined as
moderate/severe if it required a hospital admission, emergency department presentation, an unscheduled visit to a doctor or a course of oral
steroids due to asthma. a) The percentage of women who experienced an exacerbation or loss of control as gestation progressed. b) The
percentage of all asthma exacerbations or losses of control according to the number of weeks of gestation. c) The cumulative number of
exacerbations or losses of control as gestation progressed within the entire population.
TABLE 2 Maternal characteristics associated with moderate or severe asthma exacerbations
during pregnancy
Exacerbation No exacerbation p-value Relative risk (95% CI)
Subjects n 41 148
Maternal age years 25.9±5.8 26.2±5.6 0.795 0.99 (0.95–1.04)
BMI kg·m−2 29.1±7.5 28.3±7.2 0.536 1.01 (0.98–1.05)
BMI category 0.701
Normal weight 17 (41.5) 59 (39.9) Reference
Overweight 8 (19.5) 38 (25.7) 0.78 (0.37–1.66)
Obese 16 (39.0) 51 (34.5) 1.07 (0.59–1.94)
Weight gain during pregnancy kg 9.8±7.2 11.0±6.5 0.273 0.98 (0.93–1.02)
Parity 0.699
0 18 (43.9) 60 (40.5) 0.90 (0.52–1.55)
⩾1 23 (56.1) 88 (59.5)
Smoking status 0.557
Never/former smoker 29 (70.7) 99 (66.9) Reference
Quit smoking during pregnancy 3 (7.3) 20 (13.5) 0.58 (0.19–1.73)
Current smoker 9 (22.0) 29 (19.6) 1.05 (0.54–2.01)
Baseline ICS use 0.155
Yes 17 (41.5) 44 (29.7) 1.49 (0.87–2.55)
No 24 (58.5) 104 (70.3)
Data are presented as mean±SD or n (%), unless otherwise stated. BMI: body mass index; ICS: inhaled
corticosteroid.
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We observed that 20% of women experienced an exacerbation during pregnancy which is in line with the
prevalence of exacerbations in mixed socioeconomic status populations of pregnant women [10]. More
than 50% of all exacerbations occurred by 20 weeks of gestation, which is interesting given that most
studies of pregnancy, including our previous projects, do not recruit women until later in gestation
(>18 weeks gestation) [7, 12] and miss an important early time point for intervention and maintaining
asthma control. Our previous work in a mixed socioeconomic status population of pregnant asthmatic
women observed a decrease in the frequency of exacerbations after 34 weeks gestation [5], but this may be
due to study design rather than a real decrease over gestation. The current data suggest that the risk of
poor asthma control and exacerbations continues until the end of pregnancy. This may be an effect
specific to this particular population or it could be due to a major strength of this particular study in
collecting data on asthma outcomes up until delivery.
Loss of control and in particular recurrent loss of control as measured at each visit appears to have a
greater impact on perinatal outcome in this population of women. Aside from all the problems associated
with social disadvantage, the risks for a loss of control were age, BMI, cigarette use and ICS use, which are
similar to previous studies examining risk factors associated with exacerbations [5]. A population-based
study of 4434 asthmatic women examined ICS treatment pre-pregnancy and during pregnancy [25]. It was
found that 50% of all women stopped or reduced their ICS intake with pregnancy and 8.2% exacerbated
with cessation, while 20% of all other women exacerbated. Women using ICS were more likely to
exacerbate, which is due to the confounder of asthma severity [25]. Severe asthma increases the
requirement for ICS treatment and asthma severity increases the risk of an exacerbation. In our cohort,
women with recurrent loss of control are probably similar to findings from previous studies [25] in that
ICS use is a reflection of asthma severity, and therefore, they are more susceptible to worsening disease in
pregnancy especially if there is a lack of compliance with medication. Previous work has demonstrated that
cigarette use in pregnancy is associated with worsening asthma and an increased incidence of
exacerbations [15], which may also apply to an increased risk of loss of control as demonstrated in this
study. Age being a risk factor is interesting, but may be an interaction with asthma and smoking as the
combination of these factors are known to contribute to more airway obstructions with age [26].
There was a high prevalence of overweight and obese women in the current study population, which is in
line with state wide prevalence. There is some data to suggest overweight and obesity is associated with
TABLE 3 Perinatal characteristics of pregnancies complicated by a moderate or severe exacerbation
Male Female
Severe exacerbation No exacerbation p-value Severe exacerbation No exacerbation p-value
Subjects n 24 73 17 75
Gestational age days 277±12 270±20 0.108 277±12 273±12 0.288
Birthweight g 3496±461 3323±758 0.294 3461±460 3291±591 0.271
Birthweight centile 47.9±32.4 48.3±31.2 0.954 57.4±26.2 45.6±30.5 0.143
Delivery method 0.560 0.756
Vaginal 14 (58.3) 50 (68.5) 11 (64.7) 55 (73.3)
Elective LSCS 3 (12.5) 9 (12.3) 3 (17.6) 10 (13.3)
Emergency LSCS 7 (29.2) 14 (19.2) 3 (17.6) 10 (13.3)
Labour onset 0.772 1.000
SOL 14 (58.3) 37 (50.7) 9 (52.9) 40 (53.3)
IOL 6 (25.0) 24 (32.9) 6 (35.3) 23 (30.7)
None 4 (16.7) 12 (16.4) 2 (11.8) 12 (16.0)
Birth length cm 50.2±2.1 49.7±3.9 0.557 50.1±1.9 49.0±2.2 0.069
Head circumference cm 35.4±1.1 34.6±2.3 0.114 34.6±1.7 34.3±1.7 0.455
Preterm birth 0.176 1.000
No 23 (95.8) 61 (83.6) 16 (94.1) 67 (89.3)
Yes 1 (4.2) 12 (16.4) 1 (5.9) 8 (10.7)
SGA 0.726 1.000
No 22 (91.7) 64 (87.7) 15 (88.2) 64 (85.3)
Yes 2 (8.3) 9 (12.3) 2 (11.8) 11 (14.7)
Apgar Score
1 min 8±2 8±1 0.967 8±1 8±2 0.191
5 min 9±1 9±1 0.449 9±1 9±1 0.700
Data are presented as mean±SD or n (%), unless otherwise stated. LSCS: lower segment caesarean section; SOL: spontaneous onset labour;
IOL: induction of labour; SGA: small for gestational age.
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worsening asthma in nonpregnant adults [27]. Overweight or obesity may both impact on the airway via
similar mechanisms that include systemic inflammation, airway hyperresponsiveness and the mechanical
impact of weight itself on thoracic cavity function [28]. The data from this study suggests obesity itself has
no impact on the risk of recurrent loss of control, but overweight women are at risk. This may be due to a
difference in other risk factors such as smoking between obese and overweight women. Furthermore it
TABLE 4 Maternal characteristics associated with recurrent uncontrolled asthma
Recurrent uncontrolled asthma Controlled asthma p-value Relative risk (95% CI)
Subjects n 30 159
Maternal age years 28.0±5.6 25.7±5.4 0.039 1.06 (1.01–1.11)
BMI kg·m−2 30.4±7.8 28.1±7.0 0.1 1.03 (0.99–1.07)
BMI category 0.189
Normal weight 9 (30.0) 67 (42.1) Reference
Overweight 6 (20.0) 40 (25.2) 1.10 (0.42–2.89)
Obese 15 (50.0) 52 (32.7) 1.89 (0.89–4.04)
Weight gain during pregnancy kg 7.9±7.2 11.3±6.2 0.009 0.92 (0.84–0.99)
Parity <0.001 N/A
0 0 78 (49.1)
⩾1 30 (100.0) 81 (50.9)
Smoking status 0.002
Never/former smoker 15 (50.0) 113 (71.1) Reference
Quit smoking during pregnancy 2 (6.7) 21 (13.2) 0.74 (0.18–3.03)
Current smoker 13 (43.3) 25 (15.7) 2.92 (1.53–5.58)
Baseline ICS use 0.007
Yes 16 (53.3) 45 (28.3) 2.40 (1.25–4.60)
No 14 (46.7) 114 (71.7)
Data are presented as mean±SD or n (%), unless otherwise stated. BMI: body mass index; ICS: inhaled corticosteroid; N/A: not applicable.




Controlled asthma p-value Recurrent
uncontrolled asthma
Controlled asthma p-value
Subjects n 12 85 18 74
Gestational age days 266±24 272±18 0.308 272±9 275±13 0.467
Birthweight centile 49.8±34.1 48.0±31.2 0.853 41.2±35.5 49.4±28.5 0.302
Birth weight g 3280±761 3378±693 0.652 3182±646 3357±550 0.246
Delivery method 0.578 0.021
Vaginal 9 (75.0) 55 (64.7) 9 (50.0) 57 (77.0)
Elective LSCS 2 (16.7) 10 (11.8) 6 (33.3) 7 (9.5)
Emergency LSCS 1 (8.3) 20 (23.5) 3 (16.7) 10 (13.5)
Labour onset 1 0.039
SOL 6 (50.0) 45 (52.9) 6 (33.3) 43 (58.1)
IOL 4 (33.3) 26 (30.6) 6 (33.3) 23 (31.1)
None 2 (16.7) 14 (16.5) 6 (33.3) 8 (10.8)
Birth length cm 50.0±2.0 49.8±3.7 0.84 48.9±1.9 49.3±2.2 0.507
Head circumference cm 35.5±1.3 34.7±2.2 0.281 34.0±1.8 34.4±1.6 0.348
Preterm birth 0.201 1
No 9 (75.0) 75 (88.2) 16 (88.9) 67 (90.5)
Yes 3 (25.0) 10 (11.8) 2 (11.1) 7 (9.5)
SGA 1 0.018
No 11 (91.7) 75 (88.2) 12 (66.7) 67 (90.5)
Yes 1 (8.3) 10 (11.8) 6 (33.3) 7 (9.5)
Apgar Score
1 min 8±2 8±1 0.395 8±2 8±1 0.442
5 min 9±1 9±1 0.805 9±2 9±1 0.746
Data are presented as mean±SD or n (%), unless otherwise stated. LSCS: lower segment caesarean section; SOL: spontaneous onset labour;
IOL: induction of labour; SGA: small for gestational age.
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may also be related to dietary intake in this population as we have reported recently that asthmatic women
who consumed a diet high in fat, sugar and refined grains were twice as likely to have uncontrolled asthma
during pregnancy regardless of BMI [29].
Poor perinatal outcomes associated with maternal asthma appeared to vary with fetal sex. In the current
study we observed a greater incidence of SGA female babies in the presence of recurrent uncontrolled
asthma. Previous studies have reported a higher incidence of SGA females with the combination of
maternal smoking and asthma [30]. Several mechanistic studies have shown that there are sex-specific
differences in the fetal response to maternal asthma that may be conferred by a difference in
glucocorticoid sensitivity of the male and female placenta [31, 32]. These findings suggest males and
females respond differently to the presence of maternal asthma and institute different strategies in relation
to growth, which may also contribute to difference in perinatal outcomes.
Asthma was not observed to worsen in the presence of a female fetus in the current study, but previous
studies have reported a higher incidence of maternal hospitalisations for asthma in women pregnant with
a female [33], and reduced maternal lung function and an increased requirement for ICS in women
pregnant with a female [7]. However, this remains controversial as large epidemiological studies did not
find any difference in maternal exacerbations or daily ICS dose in asthmatic women pregnant with a male
or female fetus [34].
While this study was sufficiently powered to assess asthma exacerbations and control during pregnancy, it
was underpowered to examine less common perinatal outcomes such as preterm birth. The strengths of
this study are reflected in the detailed and prospective collection of data on asthma status and perinatal
outcomes. A key challenge related to studies involving asthmatic pregnancies lies in the accurate
identification of asthma control status and exacerbations. While validated tools such as the ACQ can be
used in the evaluation of asthma control at any point in time [23], no such validated tools are available
for identifying exacerbations [35, 36]. A common approach for defining exacerbations has been to use
any event requiring a hospital admission, emergency department presentation, an unscheduled visit to a
doctor or a course of oral steroids due to asthma. How well each of these events relates to actual asthma
control status remains unclear. For example, women who have greater self-awareness of potentially
deteriorating asthma may more readily visit their doctor or the emergency department to seek additional
help, while those with poor self-awareness may avoid seeking necessary additional help. This could lead to
a situation in which those with greater health-seeking behaviours may appear to experience more
exacerbations during pregnancy, but could in turn have better pregnancy outcomes as a result of
subsequent improved asthma self-management. In contrast, those with impaired health-seeking
behaviours may appear to experience fewer exacerbations, but have worse pregnancy outcomes due to
poor asthma self-management. The results of this study in a socially disadvantaged population lend
support to these criticisms of the common definition of asthma exacerbations and provide an argument
for the preferred use of validated tools such as the ACQ, which does not rely on self-awareness or
health-seeking behaviours for assessing asthma-related outcomes during pregnancy. Many previous studies
required retrospective collection of exacerbation data from medical records [10, 37, 38] and we speculate,
based our current data, that while exacerbations identified from medical records may be a surrogate
marker for persistently poorly controlled asthma during pregnancy, their predictive value in identifying
persistently poorly controlled asthma during pregnancy could be biased by the characteristics of the
population being studied. Therefore, a major strength of this study is that it provides new evidence that
chronically or persistently uncontrolled asthma may be a greater driver for poor perinatal outcomes than
an acute exacerbation.
Conclusion
The current study provides some new and novel insights into the course of asthma during pregnancy,
especially the identification that 50% of all exacerbations and losses of control occur before 20 weeks of
gestation. This highlights the need for clinicians to focus on maintaining asthma control during pregnancy
through the introduction of asthma education and self-management skills pre-pregnancy to avoid early
gestation events that may detrimentally affect placentation and fetal growth. Interestingly, recurrent
uncontrolled asthma had the greatest impact on perinatal outcomes, rather than exacerbations, suggesting
there is a need for asthma management support during pregnancy to ensure women can maintain asthma
control. We speculate that in combination with the identified risk factors for recurrent uncontrolled
asthma reported in this paper, which include body weight, cigarette use, ICS use and maternal age, there
may also be financial stressors, different purchasing priorities and poor health literacy that could influence
ICS use and adherence in this socially disadvantaged population. The key to resolving these issues is to
have a more structured approach to asthma education and self-management pre-pregnancy and then a
clinically integrated service that encompasses respiratory care with antenatal care.
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